SynthesisFrontiers in neurology2025
Levetiracetam versus phenytoin/fosphenytoin for second-line treatment of children with convulsive status epilepticus: an up-to-date meta-analysis and systematic review of randomized controlled trials.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of levetiracetam intravenous infusion combined with midazolam continuous pump infusion for stepwise emergency treatment of convulsive status epilepticus in children: a retrospective cohort study.American journal of translational research · 2026Article
- Let's retire phenytoin! Levetiracetam as the first choice in the treatment of convulsive status epilepticus.Arquivos de neuro-psiquiatria · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of levetiracetam versus phenytoin/fosphenytoin as second-line treatments in children with convulsive status epilepticus (CSE). Methods: A systematic search identified randomized controlled trials comparing levetiracetam with phenytoin/fosphenytoin to treat CSE in children. Fourteen studies involving 2,197 patients were included in the meta-analysis. Results: No significant difference was found between the two treatments regarding seizure cessation (odds ratio (OR): 1.18, 95% confidence interval (CI): 0.94-1.48; Conclusion: Levetiracetam is as effective as phenytoin/fosphenytoin to control seizures in children with CSE and is associated with fewer seizure recurrences and adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.